CA2911902A1 - Radiomitigating pharmaceutical formulations - Google Patents

Radiomitigating pharmaceutical formulations Download PDF

Info

Publication number
CA2911902A1
CA2911902A1 CA2911902A CA2911902A CA2911902A1 CA 2911902 A1 CA2911902 A1 CA 2911902A1 CA 2911902 A CA2911902 A CA 2911902A CA 2911902 A CA2911902 A CA 2911902A CA 2911902 A1 CA2911902 A1 CA 2911902A1
Authority
CA
Canada
Prior art keywords
compound
day
compounds
substituted
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2911902A
Other languages
English (en)
French (fr)
Inventor
William Mcbride
Ewa MICEWICZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA2911902A1 publication Critical patent/CA2911902A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2911902A 2013-05-07 2014-05-07 Radiomitigating pharmaceutical formulations Abandoned CA2911902A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361820447P 2013-05-07 2013-05-07
US61/820,447 2013-05-07
PCT/US2014/037110 WO2014182789A2 (en) 2013-05-07 2014-05-07 Radiomitigating pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CA2911902A1 true CA2911902A1 (en) 2014-11-13

Family

ID=51867859

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2911902A Abandoned CA2911902A1 (en) 2013-05-07 2014-05-07 Radiomitigating pharmaceutical formulations

Country Status (11)

Country Link
US (3) US9783515B2 (enExample)
EP (1) EP2994457B1 (enExample)
JP (1) JP2016523830A (enExample)
KR (1) KR20160005356A (enExample)
CN (1) CN105579439B (enExample)
AU (1) AU2014262764B2 (enExample)
CA (1) CA2911902A1 (enExample)
ES (1) ES2860949T3 (enExample)
IL (1) IL242493B (enExample)
SG (1) SG11201509194SA (enExample)
WO (1) WO2014182789A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130203722A1 (en) 2006-09-26 2013-08-08 Rhonda R. Voskuhl Estriol therapy for autoimmune and neurodegenerative disease and disorders
KR20160005356A (ko) * 2013-05-07 2016-01-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 방사선완화 약제학적 제형
WO2017156222A1 (en) * 2016-03-09 2017-09-14 The Regents Of The University Of California Radiomitigating compounds, compositions and methods related thereto
AU2017342551B2 (en) * 2016-10-16 2022-10-20 BCN Biosciences L.L.C. Methods of treatment and pharmaceutical compositions using BCN057 or BCN512
AU2018316185A1 (en) * 2017-08-08 2020-03-26 BCN Biosciences L.L.C. Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using compound 512
WO2023122723A1 (en) 2021-12-23 2023-06-29 The Broad Institute, Inc. Panels and methods for diagnosing and treating lung cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4159331A (en) * 1978-05-05 1979-06-26 The Upjohn Company Antihypertensive 4-aminoquinolines
SI20324A (sl) 1997-10-27 2001-02-28 Agouron Pharmaceuticals, Inc. Substituirane 4-amino-tiazol-2-il spojine kot cdk inhibitorji
US6407120B1 (en) * 1999-02-18 2002-06-18 Pfizer Inc. Neuropeptide Y antagonists
IT1313594B1 (it) * 1999-08-03 2002-09-09 Novuspharma Spa Bisplatino complessi attivi per via orale.
JP4365102B2 (ja) * 2001-04-26 2009-11-18 コーロン ライフ サイエンス インク 新規なスルホンアミド誘導体、その中間体化合物、及びその製造方法、並びにスルホンアミド誘導体を含む薬剤学的組成物
HUE032523T2 (en) * 2003-11-14 2017-09-28 Temple Univ - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for the treatment of proliferative disorders
JP2005232101A (ja) * 2004-02-20 2005-09-02 Rikogaku Shinkokai セレコキシブアミノアルキル誘導体
US7345043B2 (en) 2004-04-01 2008-03-18 Miikana Therapeutics Inhibitors of histone deacetylase
MY140912A (en) 2004-07-26 2010-01-29 Du Pont Mixtures of anthranilamide invertebrate pest control agents
US7615570B2 (en) * 2004-12-13 2009-11-10 Abbott Laboratories Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
WO2007029078A2 (en) * 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Succinimide and glutarimide derivatives as adrenergic receptor antagonists
WO2007143745A2 (en) 2006-06-09 2007-12-13 Icos Corporation Substituted phenyl acetic acids as dp-2 antagonists
EA200900496A1 (ru) 2006-09-28 2009-08-28 Эрет Терэпьютикс, Инк. Сульфонамидные соединения (варианты), содержащая их фармацевтическая композиция, способ ингибирования растворимой эпоксидгидролазы и способ лечения заболеваний, опосредованных растворимой эпоксидгидролазой
JP2011526925A (ja) 2008-07-01 2011-10-20 ザカロン ファーマシューティカルズ，インク． ヘパラン硫酸阻害剤
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
WO2010111713A2 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. N-linked glycan biosynthesis modulators
WO2012087889A2 (en) * 2010-12-20 2012-06-28 The Ohio State University Research Foundation Dna methylation inhibitors
US9217000B2 (en) * 2011-02-18 2015-12-22 Univerisyt of Pittsburgh—of the Commonwealth System of Higher Education Targeted nitroxide agents
KR20160005356A (ko) * 2013-05-07 2016-01-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 방사선완화 약제학적 제형

Also Published As

Publication number Publication date
US20160221976A1 (en) 2016-08-04
CN105579439B (zh) 2018-10-19
US9840483B2 (en) 2017-12-12
ES2860949T3 (es) 2021-10-05
KR20160005356A (ko) 2016-01-14
EP2994457B1 (en) 2021-01-06
US20160090369A1 (en) 2016-03-31
IL242493A0 (en) 2016-02-01
AU2014262764A1 (en) 2015-12-17
US9783515B2 (en) 2017-10-10
WO2014182789A2 (en) 2014-11-13
CN105579439A (zh) 2016-05-11
AU2014262764B2 (en) 2018-11-15
US20180162827A1 (en) 2018-06-14
IL242493B (en) 2020-08-31
JP2016523830A (ja) 2016-08-12
WO2014182789A3 (en) 2014-12-11
EP2994457A2 (en) 2016-03-16
SG11201509194SA (en) 2015-12-30
EP2994457A4 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
US20180162827A1 (en) Radiomitigating pharmaceutical formulations
US10246406B2 (en) Beta-substituted beta-amino acids and analogs as chemotherapeutic agents and uses thereof
EA022311B1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EP3893945A1 (en) Cromolyn esters and uses thereof
EP3515449A1 (en) Chromobox protein inhibitors and uses thereof
WO2022146914A1 (en) Cromolyn derivatives and uses thereof
TW201808269A (zh) 用於治療搔癢症及／或發癢之方法
AU2020337892B2 (en) Methods of treatment using BCN057 and BCN512
US8598180B2 (en) Tetrahydroindolone derivatives for treatment of neurological conditions
WO2016196961A1 (en) Ligands selective to alpha 6 subunit-containing gabaa receptors ans their methods of use
US20230113944A1 (en) Compositions and methods for the treatment of neurodegenerative diseases
WO2017156222A1 (en) Radiomitigating compounds, compositions and methods related thereto
US20220184084A1 (en) Compositions and methods for treating cushing's disease
US20210238124A1 (en) Acetylated prodrugs for delivery across the blood-brain barrier
WO2022182895A1 (en) Compounds and methods for treating congenital erythropoietic porphyria
WO2021188667A1 (en) Targeted degraders of aberrant tau based on the pet tracer pbb3
JPWO2020059841A1 (ja) プリオン病治療薬
HK1099244B (en) Tetrahydroindolone derivatives for treatment of neurological conditions

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200831